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3 
RESEARCH IN CONTEXT  51 
Evidence before study 52 
Although the role of IGRAs in diagnosis of active TB is unclear, their use in clinical practice 53 
is common. A comprehensive systematic review and meta-analysis published in 2011 54 
describes data from studies evaluating diagnostic accuracy of IGRAs in active TB up to 55 
November 2009. We therefore searched PubMed for original research studies published in 56 
any language between December 2009 and June 2018, using search terms for tuberculosis 57 
AND interferon gamma release assays, T-SPOT.TB or Quantiferon AND diagnosis, 58 
evaluation, rule-in or rule-out. The evidence-base to-date suggests that current IGRAs have 59 
insufficient specificity to rule in TB and insufficient sensitivity to rule out TB. However, this 60 
is derived primarily from studies that are either small, low quality, or not representative of 61 
patient populations seen in real-life clinical practice. Only one large prospective cohort study 62 
embedded in routine practice was identified, but in a high TB-incidence setting. Thus, fifteen 63 
years after introduction of IGRAs, the ability of policy-makers in low TB-incidence settings 64 
to generate recommendations and guidelines for the role of IGRAs in active TB is still 65 
hampered by a paucity of reliable and informative evidence.   66 
Added value of this study 67 
This is the largest prospective study specifically to define the role of IGRAs in diagnosis of 68 
active TB in a low TB incidence setting. Because the study was multicentre and embedded in 69 
routine clinical practice in England, and recruited patients representing the full natural 70 
clinical spectrum of TB, the results are generalisable to other high income, low incidence 71 
settings. By demonstrating that existing IGRAs have no useful role in diagnosis of active TB, 72 
it resolves a major clinical uncertainty and represents a significant new high-quality 73 
component of the evidence-base. Simultaneous evaluation of second-generation IGRA 74 
4 
identifies this as a potentially useful high-sensitivity triage test that meets a major unmet 75 
clinical need. 76 
Implications of all the available evidence 77 
Results from this and previous studies can now be used to generate evidence-based national 78 
guidelines and recommendations for TB diagnosis. Specifically, neither T-SPOT.TB nor 79 
QFT-GIT have sufficient sensitivity or negative predictive value (NPV) to rule out a 80 
diagnosis of TB. Taken together with their low specificity and consequent inability to rule in 81 
a diagnosis of TB, existing IGRAs do not have a clinically useful role in the diagnostic work-82 
up of TB. The finding that the second-generation IGRA may have sufficiently high 83 
sensitivity, low negative likelihood ratio and high NPV to serve as a triage test to help rule-84 
out a diagnosis of TB within 24 hours indicates a clinically useful role for this novel test and 85 
provides the basis for evidence-based guidelines on its use in low incidence settings once it is 86 
widely available post-licensure. 87 
 88 
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ABSTRACT  104 
Background 105 
The role of interferon-gamma release assays (IGRAs) in diagnosis of active tuberculosis (TB) 106 
is unclear, yet they are commonly used in low-TB-incidence countries. This study sought to 107 
resolve this clinical uncertainty by determining the diagnostic accuracy and role of current 108 
and second-generation IGRAs in the diagnostic assessment of suspected TB in a low-109 
incidence setting.  110 
Methods 111 
This was a prospective cohort study of 1,060 adults with suspected TB, conducted in routine 112 
secondary care in England. Patients were tested for M. tuberculosis (Mtb) infection at 113 
baseline using current and second-generation IGRAs, the latter incorporating novel Mtb 114 
antigens, and followed up for 6-12m to establish definitive diagnoses. Sensitivity, specificity 115 
and positive and negative likelihood ratios (LRs) and predictive values (PVs) of the tests for 116 
TB were determined. 117 
Findings 118 
TB was diagnosed in 363 (43%) of 845 patients included in analyses. Sensitivity of T-119 
SPOT.TB was 81.4% (95%CI 76.6-85.3%), higher than Quantiferon-Gold In-Tube at 67.3% 120 
(95%CI 62.0-72.1%). Second-generation IGRA had higher sensitivity than current tests, at 121 
94.0% (95%CI 90.0–96.4%) for culture-confirmed TB and 89.2% (95%CI 85.2–92.2%) when 122 
including highly-probable TB, giving a negative LR for all TB of 0.13 (95%CI 0.10-0.19). 123 
Specificity ranged from 86.2% (95%CI 82.3-89.4%) for T-SPOT.TB to 80.0% (95%CI 75.6-124 
83.8%) for second-generation IGRA. 125 
6 
Interpretation 126 
Currently-available IGRAs lack sufficient accuracy for diagnostic evaluation of suspected 127 
TB. Second-generation tests, however, may have sufficiently high sensitivity, low negative 128 
LR and correspondingly high negative PV in low-incidence settings to facilitate prompt rule-129 
out of TB. 130 
Funding 131 
This study was funded by the National Institute for Health Research.  132 
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INTRODUCTION  153 
Prompt diagnosis and treatment of active tuberculosis (TB) are essential for optimal patient 154 
outcomes and preventing onward transmission in the community and healthcare facilities.
1
 155 
However, diagnostic assessment of suspected TB can be lengthy, costly and burdensome for 156 
patients and healthcare systems,
2
 often resulting in significant delays in diagnosis and 157 
treatment of other diseases in cases where suspected TB is eventually ruled out. Improving 158 
and accelerating diagnostic evaluation thus remains a clinical and public health priority in 159 
high-income, low-incidence countries, as well as high-burden regions. Recently, great 160 
advances in molecular diagnostics, such as GeneXpert (Cepheid Inc, Sunnyvale, CA, USA), 161 
have improved the speed and accuracy of microbiologic diagnosis and enabled prediction of 162 
antibiotic susceptibility.
3
 However, whilst such tests have high specificity (which is important 163 
for ‘rule-in’), they have insufficient sensitivity to rule out TB and require clinical specimens 164 
from anatomical disease sites, often requiring resource-intensive invasive procedures.
4
 A 165 
blood test of high diagnostic sensitivity could help to promptly (e.g. in 24h) triage patients at 166 
clinical presentation (Appendix: Supplementary Panel, page 1); this would address a major 167 
unmet clinical need and has been prioritised by the World Health Organisation (WHO).
5
 168 
Given the paucibacillary nature of most cases of culture-negative TB, such a test would likely 169 
be based on measurement of immune responses to M. tuberculosis (Mtb) rather than direct 170 
detection of the bacteria or nucleic acids.  171 
Interferon-gamma release-assays (IGRAs) are regulatory-approved immune-based blood tests 172 
for detecting Mtb infection. By measuring T-cell responses to two strongly immunogenic but 173 
highly specific Mtb antigens (ESAT-6 and CFP-10), they are not confounded by prior 174 
Bacillus Calmette-Guérin (BCG) vaccination and provide higher diagnostic specificity than 175 
8 
the tuberculin skin test (TST).
6
 Since Mtb infection is a pre-requisite for TB disease, a 176 
negative IGRA result could potentially rule-out a diagnosis of TB disease (i.e. exclude TB 177 
from the differential diagnosis), though prior evidence suggests the sensitivity of current 178 
IGRAs may be insufficient to fulfil this triage function.
1,7–9
  179 
Although established as the new standard-of-care for diagnosing latent TB infection (LTBI), 180 
IGRAs are currently not recommended in diagnosis of active TB other than in specific 181 
scenarios, such as paediatric TB, with caveats around interpretation and level of expertise 182 
required.
10,11
 However, development of definitive recommendations has been hindered by a 183 
lack of robust and informative evidence. Most studies of diagnostic accuracy of IGRAs in 184 
active TB to date are retrospective reviews of hospital records and TB registry data or small-185 
scale case-control studies, typically not representative of the heterogeneous patient 186 
population seen in real-life clinical practice. Although one large prospective cohort study 187 
embedded in routine practice and including head-to-head comparison of T-SPOT.TB and 188 
QFT-GIT was recently published, this was in a high TB-incidence setting.
12
 Prospective 189 
cohort studies conducted in low-incidence settings have been substantially smaller.
1,8 190 
Given the shortfalls associated with available TB diagnostics, IGRAs continue to be used 191 
widely in clinical practice in the UK, albeit resulting in complexities and challenges in 192 
interpretation of results.
11
 A large-scale prospective head-to-head comparison of diagnostic 193 
performance of IGRAs in routine practice is therefore required to conclusively define what, if 194 
any, clinical role they have in diagnosis of active TB, allowing development of evidence-195 
based and authoritative recommendations in this setting. 196 
Discovery of other highly-specific Mtb antigens as strongly immunogenic as ESAT-6 and 197 
CFP-10 presents an opportunity to develop second-generation IGRAs of higher 198 
sensitivity.
13,14
 Furthermore, they may allow development of an ‘ESAT-6-free’ IGRA for 199 
application in populations vaccinated with new ESAT-6-based TB vaccines, as previously 200 
9 
described.
15
 Studies suggest adaptation of existing IGRAs with these novel antigens is 201 
possible,
1,14,16
 but no large-scale prospective clinical evaluation of this novel approach has 202 
been conducted in routine practice in a low TB-incidence setting.  203 
We therefore sought to evaluate the clinical utility of existing IGRAs, T-SPOT.TB (Oxford 204 
Immunotec plc, Abingdon, UK) and Quantiferon-Gold In-tube (QFT-GIT; Qiagen NV), and 205 
second-generation IGRAs in patients presenting with suspected TB in UK clinical practice.    206 
 207 
METHODS  208 
We conducted a prospective, multicentre, cohort study in routine clinical practice to 209 
determine the diagnostic accuracy of commercially-available and second-generation IGRAs 210 
in active TB. A within-patient design was used to compare test accuracy by performing all 211 
IGRAs on blood samples from each study participant, with the presence or absence of active 212 
TB verified using a composite reference standard (Table 1).
1
 This design minimises between-213 
patient variability. The study was approved by Camden and Islington National Research 214 
Ethics Committee (11/H0722/8). The study protocol is available at https://njl-215 
admin.nihr.ac.uk/document /download/2006627, and a STARD checklist is provided in the 216 
Appendix (Supplementary Checklist, pages 2-3). 217 
Study participants 218 
Adult inpatients and outpatients presenting with suspected active TB (based on signs and 219 
symptoms assessed by the attending hospital clinician) were consecutively enrolled from ten 220 
National Health Service (NHS) hospitals in five UK cities (London, Slough, Oxford, 221 
Leicester and Birmingham). Patients were enrolled at presentation to infectious disease and 222 
respiratory medicine secondary care services, before a final diagnosis was made, and a wide 223 
spectrum of pre-test probabilities for active TB were included. Exclusion criteria were limited 224 
10 
to age <16y and inability/unwillingness to provide informed consent. Centres were selected 225 
to ensure the population was representative of ethnic mix and range of co-morbidities.  226 
Participant enrolment and follow-up  227 
Participants were first seen by research nurses at enrolment. Following consent, a baseline 228 
blood sample was drawn and data collected in a case report form on the demographics and 229 
medical history of the participant, and investigations performed in their routine diagnostic 230 
work-up. Participants were followed up two and six months thereafter with data collected on 231 
any subsequent investigations, test results and clinical diagnoses, and response to TB 232 
treatment if initiated. Patients with a definitive non-TB diagnosis who were discharged from 233 
routine care were not required to attend follow-up visits but, where necessary, data were 234 
collected from hospital records up to 12 months after enrolment to identify final diagnoses 235 
made by hospital clinicians. 236 
Diagnosis and diagnostic categorisation  237 
Participants were investigated in routine practice under the direction of the infectious disease 238 
or respiratory medicine attending physician. After completion of follow-up in this routine 239 
hospital setting, participants’ final diagnoses were verified using a composite reference 240 
standard
1
 by a panel of ≥4 respiratory medicine and infectious disease clinicians specialising 241 
in TB. The panel assessed anonymised clinical data (patient demographics, medical history, 242 
TB symptoms, previous TB information, TB exposure history, current medication, human 243 
immunodeficiency virus (HIV) status, relevant clinical correspondence, test results during 244 
diagnosis and follow-up, and any other relevant clinical information) whilst blinded to all 245 
IGRA results (including IGRAs carried out as part of routine practice at recruiting sites). 246 
Diagnoses of all participants were categorised into the following groups, as previously 247 
defined
1
 (Table 1): definite TB (category 1); highly-probable TB (category 2); clinically 248 
indeterminate (category 3); and non-TB (category 4). Category 4 participants were sub-249 
11 
divided based on risk factors for LTBI (Table 1). Final diagnoses and diagnostic categories 250 
were determined by consensus across the panel.  251 
Laboratory procedures 252 
Blood samples (35ml) were collected into heparinised and QFT-GIT blood collection tubes 253 
from all participants at enrolment, before any diagnosis was made. QFT-GIT and T-254 
SPOT.TB were carried out and interpreted in real-time at the TB Research Centre (Imperial 255 
College London) according to the manufacturer’s instructions, and as described in Whitworth 256 
et al.
6 
The second-generation IGRA used the T-SPOT.TB platform and incorporated ESAT-6, 257 
CFP-10 and Rv3615c; the ‘ESAT-6-free’ IGRA incorporated CFP-10, Rv3615c and 258 
Rv3879c. Further details on assay methods and interpretation of results are provided in the 259 
Appendix (Supplementary Methods, pages 4-5). Laboratory scientists performing study 260 
IGRAs were blinded to all clinical information, diagnoses and personal identifiers. 261 
Statistical Analyses 262 
The study was powered to detect a 10% difference in sensitivity between T-SPOT.TB and 263 
QFT-GIT, assuming a sensitivity of 85% for T-SPOT.TB and 75% for QFT-GIT.
1,7–9
 264 
Accounting for the paired nature of the data and assuming independence of errors,
16
 855 265 
patients (after loss-to-follow-up (LTFU)/withdrawal and missing/excluded index/reference 266 
test results) were required to detect this difference at the 5% significance level (two-tailed) 267 
with 90% power, based on a predicted 40% prevalence of active TB in the study population. 268 
Sensitivity, specificity, positive and negative predictive values (PPV; NPV), and positive and 269 
negative likelihood ratios (PLR; NLR) for each test were calculated. Ninety-five percent 270 
confidence intervals (CIs) were calculated using the Wilson method for proportions
18,19 
and 271 
the method by Simel et al for LRs.
20
 All patients in diagnostic categories 1, 2 and 4 were 272 
included in analyses (Table 1); category 3 patients were reported but not included in analyses.  273 
12 
Patients with indeterminate IGRA or borderline TSPOT-TB results were excluded from 274 
primary analyses, but included as test-positives in sensitivity analyses. Sensitivity analyses 275 
were also conducted to investigate the impact of (1) excluding category 2 patients on IGRA 276 
sensitivity and (2) excluding category 4A-C patients on IGRA specificity.  To compare the 277 
accuracy of two IGRAs, we fitted separate generalized estimating equation (GEE) models for 278 
patients with and without active TB to estimate differences in sensitivity and specificity, 279 
respectively. This approach exploits the paired nature of the data whilst allowing use of all 280 
available data if test results were missing for either IGRA. We computed ratios of 281 
sensitivities (relative-sensitivity) and specificities (relative-specificity) from the GEE models 282 
using a post-estimation procedure with CIs computed using the delta method. Analyses were 283 
performed using Stata, version 13.0 (Stata, College Station, Texas). 284 
Role of the funding source 285 
The study funder, the National Institute for Health Research (NIHR), played no role in study 286 
design, data collection, analysis or interpretation, or writing of the report. The corresponding 287 
author had full access to all data in the study and had final responsibility for the decision to 288 
submit for publication. 289 
 290 
RESULTS  291 
Participant flow 292 
Participant flow in the study is shown in Figure 1. Patients (n=1,060) with suspected active 293 
TB were consented and enrolled between 25 November 2011 and 31 August 2013. Those 294 
with a history of prior TB diagnosis (n=99) were excluded from analyses, as in previous 295 
studies.
12
 Additionally, 116 patients were excluded for reasons provided in Figure 1, giving a 296 
final study population of 845 patients. 297 
Demographic & clinical characteristics  298 
13 
Demographic and clinical characteristics for the final study population are shown in Table 2. 299 
The median age of the cohort was 38y (range 16-86y); 501/845 (59%) were male, and 300 
412/845 (48%) were of Indian Subcontinent origin. One or more co-morbidities were 301 
reported in 427/845 (51%) participants (Table 2). Medications at presentation are shown in 302 
the Appendix (Supplementary Table 1, page 6). The most common symptoms reported at 303 
presentation were cough, weight-loss and lethargy (Appendix: Supplementary Table 2, page 304 
7). 305 
Diagnostic classification of patients 306 
Among the study cohort, 363/845 patients (43%) had a final diagnosis of active TB (Table 1); 307 
261/845 (31%) culture-confirmed (category 1), and 102/845 (12%) highly-probable 308 
(Category 2). Of all active TB cases (categories 1 and 2), 129/363 (36%) were pulmonary, 309 
189/363 (52%) were extra-pulmonary and 45/363 (12%) were both (Table 3); most 154/363 310 
(42%) had lymph node involvement. Of Mtb isolates undergoing drug-susceptibility testing, 311 
21/261 (6%) were drug-resistant and one was multi-drug-resistant. TB was excluded 312 
(category 4) in 439/845 (52%) patients. These were sub-classified according to risk factors 313 
for LTBI or inactive TB into categories 4A-D in decreasing likelihood of having Mtb 314 
infection (Table 1).
1
 Most common non-TB diagnoses are listed in Table 3. Only 43/845 315 
patients (5.1%) were classified as clinically indeterminate (category 3). 316 
Diagnostic accuracy of T-SPOT.TB and QFT-GIT  317 
T-SPOT.TB and QFT-GIT results were available for 809/845 (96%) and 820/845 (97%) 318 
study participants, respectively; 805/845 (95%) patients had data for both IGRAs. Diagnostic 319 
sensitivity, specificity, PPV, NPV, PLR and NLR are shown in Table 4, with a cross-320 
tabulation of T-SPOT.TB and QFT-GIT results in patients with active TB and non-TB 321 
diagnoses provided in the Appendix (Supplementary Table 3, page 8). Sensitivity of T-322 
SPOT.TB was 84.9% (95%CI 79.5-89.0%) for culture-confirmed TB and 81.4% (95%CI 323 
14 
76.6-85.3%) for all TB, giving an NPV of 84.7% (95%CI 80.6-87.9%) and NLR of 0.22 324 
(95%CI 0.17-0.27) for all TB. Specificity was 86.2% (95%CI 82.3-89.4%) for all non-TB 325 
patients and 93.5% (95%CI 86.6-97.0%) for cases with no risk factors for LTBI (category 326 
4D). Sensitivity of QFT-GIT was 70.6% (95%CI 64.4-76.1%) for culture-confirmed TB and 327 
67.3% (95%CI 62.0-72.1%) for all TB, giving an NPV of 74.0% (95%CI 69.5-78.0%) and 328 
NLR of 0.41 (95%CI 0.35-0.48) for all TB. Specificity was 80.4% (95%CI 76.1-84.1%) for 329 
all non-TB patients and 93.4% (95%CI 86.4-96.9%) for cases with no risk factors for LTBI. 330 
Sensitivity and specificity of T-SPOT.TB were superior to QFT-GIT; relative sensitivity was 331 
1.20 (95%CI 1.12-1.29) with p<0.0001, and relative specificity was 1.07 (95%CI 1.02-1.12) 332 
with p=0.004. 333 
Diagnostic accuracy of second-generation and ESAT-6-free IGRA 334 
Second-generation and ESAT-6-free IGRA results were available for 809/845 (96%) patients 335 
(Table 4). Sensitivity of second-generation IGRA was 94.0% (95%CI 90.0-96.4%) for 336 
culture-confirmed TB and 89.2% (95%CI 85.2-92.2%) for all TB, giving an NPV of 90.0% 337 
(95%CI 86.2-92.8%) and NLR of 0.13 (95%CI 0.10-0.19) for all TB. Specificity was 80.0% 338 
(95%CI 75.6-83.8%) for all non-TB patients and 91.3% (95%CI 83.8-95.5%) for cases with 339 
no risk factors for LTBI. Sensitivity of ESAT-free IGRA was 93.4% (95%CI 89.2-96.0%) for 340 
culture-confirmed TB and 88.0% (95%CI 83.8-91.2%) for all TB, giving an NPV of 89.2% 341 
(95%CI 85.4-92.1) and NLR of 0.15 (95%CI 0.11-0.21) for all TB. Specificity was 79.6% 342 
(95%CI 75.2-83.4%) for all non-TB patients and 90.3% (95%CI 82.6-94.8%) for cases with 343 
no risk factors for LTBI. Comparing second-generation IGRA with T-SPOT.TB, relative 344 
sensitivity was 1.08 (95%CI 1.04–1.11) with p<0.0001, and relative specificity was 0.94 345 
(95%CI 0.91–0.96) with p<0.0001. For ESAT-6-free IGRA versus T-SPOT.TB, relative 346 
sensitivity was 1.07 (95%CI 1.03–1.10) with p=0.0002, and relative specificity was 0.93 347 
(95%CI 0.90–0.96) with p<0.0001. A cross-tabulation of second-generation IGRA against T-348 
15 
SPOT.TB results and table of response magnitudes for each individual antigen are provided 349 
in the Appendix (Supplementary Tables 4 (page 9) and 5 (page 10) respectively). 350 
Test performance in key patient subgroups 351 
Of culture-confirmed TB cases with available smear microscopy results, 165/232 (71%) were 352 
smear-negative (57/165 with pulmonary TB, 80/165 with extra-pulmonary TB and 28/165 353 
with both). Sensitivities of T-SPOT.TB, QFT-GIT, second-generation IGRA and ESAT-6-354 
free IGRA in this population were 85.9% (95%CI 79.2%-90.7%), 68.6% (95%CI 60.9%-355 
75.4%), 93.8% (95%CI 88.5%-96.7%) and 92.9% (95%CI 87.4%-96.1%), respectively. 356 
Among HIV-infected study participants, 25/135 (19%) had a final diagnosis of active TB and 357 
108/135 (80%) had TB excluded; 27/88 (31%) diabetic participants had a final diagnosis of 358 
TB (Table 2). Sensitivity and specificity of all IGRAs for active TB in patients with HIV-359 
infection and diabetes are shown in the Appendix (Supplementary Tables 6 (page 11) and 7 360 
(page 12), respectively).  361 
Indeterminate and borderline results 362 
There was a trend towards a higher indeterminate rate for QFT-GIT (79/820; 9.6%) than 363 
T-SPOT.TB (57/809; 7.0%; p=0.07), and rates for QFT-GIT were higher than second-364 
generation IGRA (55/809; 6.8%; p=0.04) and ESAT-6-free IGRA (55/809; 6.8%; p=0.04). 365 
Most indeterminate results occurred in non-TB patients (Appendix: Supplementary Tables 3 366 
(page 8) and 4 (page 9)). T-SPOT.TB results were borderline in 17/345 (4.9%) patients with 367 
active TB and 16/423 (3.8%) with non-TB diagnoses. Lowering the cut-off of T-SPOT.TB 368 
from eight to five SFCs (thereby scoring all borderline results as positive) did not improve 369 
diagnostic performance of T-SPOT.TB or either of the second-generation IGRAs, giving only 370 
a marginal increase in sensitivity at the cost of a decrease in specificity (Supplementary Table 371 
8; page 13). Scoring both indeterminate and borderline results as positives also did not affect 372 
test performance in sensitivity analyses (Table 4, footnote f).  373 
16 
 374 
DISCUSSION  375 
This is the largest prospective cohort study embedded in real-life clinical practice to assess 376 
and compare the role of IGRAs in the evaluation of suspected pulmonary and extrapulmonary 377 
TB in a low TB-incidence setting. Although T-SPOT.TB had significantly higher sensitivity 378 
than QFT-GIT, neither assay had sufficient sensitivity or NPV to rule out a diagnosis of 379 
active TB. In contrast, the second-generation IGRA, incorporating Rv3615c alongside ESAT-380 
6 and CFP-10, had significantly higher diagnostic sensitivity than T-SPOT.TB and QFT-GIT. 381 
Interestingly, and reflecting common practice despite the absence of good evidence or 382 
guidelines supporting use of IGRAs in this setting, 35% of study patients, distributed across 383 
the recruiting sites, had IGRAs performed as part of their routine diagnostic work-up for 384 
active TB (data not shown). 385 
The NLR of 0.13 for second-generation IGRA means a negative test result would reduce the 386 
odds of TB post-test by a clinically-meaningful factor of 7.7-fold compared to pre-test. The 387 
NPV for all TB, including highly-probable cases, was 90% despite the 43% prevalence in this 388 
population presenting to urban infectious diseases and respiratory medicine services with 389 
suspected TB. Since our study was performed in routine clinical practice and encompassed 390 
the full, natural clinical spectrum of TB and non-TB diagnoses, the results are likely 391 
generalizable across clinical practice in high-income, low-incidence countries. Accordingly, 392 
in clinical settings with a low-to-moderate pre-test probability of TB, such as general medical 393 
inpatient and outpatient services or primary care, second-generation IGRA has sufficiently 394 
low NLR to almost rule out TB. For example, a negative test result would convert pre-test 395 
probabilities of 20% and 10% to post-test probabilities of 3.1% and 1.4%, respectively. This 396 
would provide a useful prompt triage of patients on initial presentation, similar to the role 397 
played by other diagnostic tests of high sensitivity and limited specificity, such as serum D-398 
17 
dimer to triage patients with low-to-moderate suspicion of venous thromboembolism.
21
 To 399 
our knowledge, other currently-available tests for TB lack required diagnostic sensitivity to 400 
fulfil this role. Although Xpert MTB/RIF Ultra has shown diagnostic sensitivity of 88%, its 401 
sensitivity in smear-negative, culture-positive TB is only 63%
3 
(and sensitivity of Xpert even 402 
lower
4
), compared to 93.8% (CI 88.6%-96.7%) for second-generation IGRA in this 403 
diagnostically challenging subgroup who frequently have paucibacillary disease. However, 404 
the very high specificity of molecular tests such as Xpert provides high PPV, enabling rule-in 405 
of active TB. Second-generation IGRA may thus play a complementary role to rapid 406 
molecular tests in the diagnostic work-up of suspected TB.  407 
Given that IGRAs are the standard-of-care for detecting LTBI,
10,11
 they will inevitably 408 
identify LTBI in cases where active TB has been excluded. Because most people with 409 
possible TB in low-burden countries are from ethnic groups with a high prevalence of 410 
LTBI,
22
 as in our study, the diagnostic specificity for active TB is low for all IGRAs, and 411 
would be lower still in high-burden countries. The enhanced diagnostic sensitivity of the 412 
second-generation IGRA was accompanied by only a modest reduction in specificity to 80%, 413 
similar to QFT-GIT. Our study confirms that the low specificity and PLR of current and 414 
second-generation IGRAs mean that a positive result cannot rule in a diagnosis of TB. 415 
Interestingly, the specificity of all IGRAs increased to 90-93% in patients with active TB 416 
excluded and no risk factors for LTBI (Category 4D). Thus, a positive IGRA result may help 417 
to keep a diagnosis of active TB in the differential diagnosis in populations with a very low 418 
prevalence of LTBI, which however is not usually the case in patient populations being 419 
assessed for possible TB. 420 
Two of the leading new TB vaccine candidates, Hybrid 1-IC31
23
 and H56:IC31,
24
 contain 421 
ESAT-6 and may induce conversion of IGRA results in vaccinated individuals. If these 422 
vaccines show protective efficacy in ongoing clinical trials and achieve licensure, ESAT-6-423 
18 
containing IGRAs will give false-positive results in vaccinated persons who are not Mtb-424 
infected, analogous to false-positive TST results in Mtb-uninfected persons with prior BCG 425 
vaccination. Diagnostic accuracy of ESAT-6-free IGRA was very similar to second-426 
generation IGRA and thus has potential to replace other IGRAs in populations immunised 427 
against TB with ESAT-6-based vaccines. 428 
Two of the most important global risk factors for TB are HIV co-infection
25
 and diabetes,
26 
429 
both of which have been reported to adversely affect IGRA performance.
27,28
 Performance of 430 
current IGRAs in patients with HIV-infection and diabetes in this study was insufficient to be 431 
of value in the diagnosis of active TB. Performance appeared to be lower in HIV-infected and 432 
diabetic subgroups, but the small numbers of patients with TB in these subgroups precluded 433 
statistical comparisons. This was also the case for other types of immunosuppression 434 
associated with TB, such as chronic kidney disease and immunosuppressive medication. 435 
Strengths of our study include the rigorous case definitions, including six-months follow-up 436 
to confirm that a diagnosis of TB was excluded where a non-TB diagnosis was not made at 437 
presentation. For highly-probable TB, we used a composite reference standard
1
 that was 438 
applied by a panel of expert and experienced clinicians, blinded to IGRA results. Despite this 439 
stringent case definition, it is likely that a proportion of patients without TB were incorrectly 440 
categorised as having highly-probable TB, which would explain why all IGRAs had lower 441 
sensitivity for highly-probable TB than for all TB, which includes culture-confirmed cases. 442 
Thus, our estimates of diagnostic sensitivity for all TB, which includes highly-probable TB, 443 
are likely conservative. This highlights the significance of increased IGRA sensitivity in 444 
culture-confirmed TB (and the importance of including this sub-group in study analyses) as 445 
this is the only population in whom TB diagnoses are definitive.  446 
Our study has some limitations. First, it does not include children, in whom the unmet clinical 447 
need for improved diagnosis of TB is high. Second, the numbers of patients with risk-factors 448 
19 
associated with immunosuppression that do (e.g. HIV-infection) or might (e.g. diabetes) 449 
affect test performance were modest, precluding clear conclusions about test performance in 450 
these subpopulations. Third, whilst blood collection and assays were performed strictly in 451 
accordance with manufacturers’ instructions, IGRAs were not performed in a routine 452 
diagnostic service laboratory, and  re-testing of new samples was not performed in cases 453 
where initial results were indeterminate or borderline (as recommended by manufacturers). 454 
Although the QFT-GIT has been replaced by the QFT-GIT-Plus since our study was 455 
conducted, its diagnostic accuracy does not appear to be significantly better than QFT-GIT 456 
and there is no evidence it is as sensitive as T-SPOT.TB.
29,30
 Therefore, our conclusion that 457 
neither existing IGRA has a clinically useful role in the evaluation of suspected active TB is 458 
unaffected by availability of QFT-GIT-Plus. 459 
In conclusion, our study provides conclusive and generalizable evidence that existing IGRAs 460 
do not have a useful role as rule-in or rule-out tests in routine clinical practice. However, 461 
second-generation IGRAs have higher sensitivity and NPV which may help to rule out a 462 
diagnosis of TB in clinical settings with a low-to-moderate prevalence of TB.  463 
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Table 1: Pre-defined criteria for case definitions and diagnostic categories.
1 631 
Diagnostic category
 
Criteria Number of 
Patients 
1: Culture-confirmed TB
a 
Microbiological culture of M. tuberculosis, AND 
suggestive clinical and radiological findings. 
261 
2: Highly-probable TB
a
 Clinical and radiological features highly suggestive 
of TB unlikely to be caused by other disease, AND a 
decision to treat made by a clinician, AND 
appropriate response to therapy, AND histology 
supportive if available. 
102 
3: Clinically indeterminate Final diagnosis of TB neither highly-probable, nor 
reliably excluded. 
43 
4: Active TB excluded   
Sub-classification   
     4A: Inactive TB Stable CXR changes, AND TST positive
b
 (if done), 
AND bacteriologically negative (if done), AND no 
clinical evidence of active disease. 
7 
     4B:  One or more risk factors for 
TB exposure
c
, TST positive
b
 
TST positive
b
, AND bacteriologically negative (if 
done) AND no clinical evidence of active disease. 
48 
     4C: One or more risk factors for 
TB exposure
c
, TST negative 
History of TB exposure, AND TST negative (if 
done). 
267 
     4D: No risk factors for TB 
exposure
c
, TST negative 
No history of TB exposure, AND TST negative (if 
done) 
117 
Total  845 
CXR, chest radiograph; TB, tuberculosis; TST, tuberculin skin test. 632 
a
Mtb culture is the gold standard test for diagnosis of active TB. However, given that even culture does not 633 
detect all TB cases, our previously-validated reference standard includes a second category for culture-negative 634 
but highly-probable active TB diagnoses, made based on other available evidence.
1
 635 
bTST using Mantoux test with  threshold ≥15mm considered positive  636 
c
Risk factors for TB exposure: recent exposure to active TB patient; born in country of high prevalence; or 637 
belonging to an ethnic group with a very high prevalence of TB (incidence >100/100,000). 638 
 639 
 640 
 641 
 642 
 643 
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 645 
Table 2: Demographics and clinical characteristics. Column percentages for each characteristic are shown. 646 
 
Characteristic 
Diagnosis as per Reference Standard
1
  
Total 
 
N=845 
Culture-
confirmed TB 
N=261 
Highly-
probable TB 
N=102 
Clinically 
indeterminate 
N=43 
Active TB 
excluded 
N=439 
Clinical setting, n (%)      
Outpatient  171 (65.5) 72 (70.6) 32 (74.4) 269 (61.3) 544 (64.4) 
Inpatient 90 (34.5) 30 (29.4) 11 (25.6) 170 (38.7) 301 (35.6) 
Median age (range), 
years 
32 (16–81) 36 (18–76) 38 (16–79) 44 (17–86) 38 (16–86) 
Male, n (%) 177 (67.8) 53 (52.0) 21 (48.8) 250 (56.9) 501 (59.3) 
Ethnic origin, n (%)      
Indian Subcontinent 167 (64.0) 61 (59.8) 16 (37.2) 168 (38.3) 412 (48.8) 
Black 50 (19.2) 22 (21.6) 10 (23.3) 102 (23.2) 184 (21.8) 
White 22 (8.4) 9 (8.8) 12 (27.9) 126 (28.7) 169 (20.0) 
Asian 16 (6.1) 6 (5.9) 5 (11.6) 14 (3.2) 41 (4.9) 
Middle Eastern 4 (1.5) 0 0 12 (2.7) 16 (1.9) 
Mixed 1 (0.4) 4 (3.9) 0 8 (1.8) 13 (1.5) 
Hispanic 1 (0.4) 0 0 7 (1.6) 8 (0.9) 
Unknown 0 0 0 2 (0.5) 2 (0.2) 
Median years in UK 
(range) 
4.9 (0.1–52.9) 6.1 (0.3–59.7) 10.5 (0.4–56.9) 13.2 (0.0–60.3) 8.3 (0.0–60.3) 
Profession, n (%)
a
      
Paid employment 130 (49.8) 52 (51.0) 21 (48.8) 214 (48.7) 417 (49.4) 
Unemployed 62 (23.8) 24 (23.5) 16 (37.2) 164 (37.4) 266 (31.5) 
Student 50 (19.2) 13 (12.8) 3 (7.0) 26 (5.9) 92 (10.9) 
Healthcare/laboratory 
worker 
16 (6.1) 9 (8.8) 2 (4.7) 24 (5.5) 51 (6.0) 
Social/prison worker 1 (0.4) 1 (1.0) 0 2 (0.5) 4 (0.5) 
Sex worker 0 1 (1.0) 0 2 (0.5) 3 (0.4) 
Unknown 2 (0.8) 2 (2.0) 1 (2.3) 7 (1.6) 12 (1.4) 
Median height (range), m 1.7 (1.4–2.0) 1.7 (1.5–1.9) 1.6 (1.5–1.8) 1.7 (1.3–2.0) 1.7 (1.3–2.0) 
Median weight (range), 
kg 
63 (35–127) 64 (40–116) 71 (37–110) 68 (38–157) 65 (35–157) 
Median BMI (range) 22 (14–48) 22 (16–42) 24 (13–45) 24 (15–47) 23 (13–48) 
BCG vaccinated, n (%) 194 (74.3) 79 (77.5) 36 (83.7) 340 (77.4) 649 (76.8) 
BCG scar visible, n (%)      
28 
Yes 172 (65.9) 72 (70.6) 29 (67.4) 283 (64.5) 556 (65.8) 
No  12 (4.6) 3 (2.9)  3 (7.0)  19 (4.3)  37 (4.4)  
Unknown  16 (6.1) 8 (7.8)  6 (14.0)  44 (10.0)  74 (8.8)  
Missing  61 (23.4) 19 (18.6)  5 (11.6)  93 (21.2)  178 (21.1)  
Recent known TB 
contact, n (%) 
70 (26.8) 25 (24.5) 12 (27.9) 83 (18.9) 190 (22.5) 
Other pre-existing 
conditions/co-
morbidities, n (%)
b 
     
None 169 (64.8) 61 (59.8) 19 (44.2) 169 (38.5) 418 (49.5) 
HIV-infected 13 (5.0) 12 (11.8) 2 (4.7) 108 (24.6) 135 (16.0) 
Diabetes 22 (8.4) 5 (4.9) 8 (18.6) 53 (12.1) 88 (10.4) 
Asthma 12 (4.6) 5 (4.9) 4 (9.3) 50 (11.4) 71 (8.4) 
Cancer 1 (0.4) 1 (1.0) 0 12 (2.7) 14 (1.7) 
Chronic/end stage 
kidney disease 
5 (1.9) 1 (1.0) 2 (4.7) 4 (0.9) 12 (1.4) 
Hepatitis C 1 (0.4) 1 (1.0) 0 10 (2.3) 12 (1.4) 
Hepatitis B 5 (1.9) 1 (1.0) 0 5 (1.1) 11 (1.3) 
Organ transplantation 0 0 0 2 (0.5) 2 (0.2) 
Sarcoidosis 1 (0.4) 0 0 0 1 (0.1) 
Other 74 (28.4) 37 (36.3) 20 (46.5) 228 (51.9) 359 (42.5) 
BMI, body mass index 647 
a
Some patients had more than one profession. 648 
b
Some patients had multiple co-morbidities. 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
 662 
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Table 3: Final diagnoses of patients with and without active TB  666 
Confirmed or highly probably TB 
N = 363 
n (%) Active tuberculosis excluded
b 
N = 439 
n (%) 
All TB 363 (100) Pneumonia 104 (23.7) 
Pulmonary  129 (35.5) Sarcoidosis 38 (8.7) 
Extrapulmonary  189 (52.1) Cancer 36 (8.2) 
Pulmonary and extrapulmonary  45 (12.4) Lower respiratory tract infection  23 (5.2) 
Site of disease
a
 Reactive lymphadenopathy  18 (4.1) 
Lungs 174 (47.9) Chest Infection 16 (3.6) 
Lymph node 154 (42.4) Exacerbation of asthma 14 (3.2) 
Pleura 26 (7.2) Upper respiratory tract infection 13 (3.0) 
Spine 16 (4.4) Non-tuberculosis mycobacterium infection 12 (2.7)  
Miliary TB (disseminated) 11 (3.0) Exacerbation of bronchiectasis 11 (2.5) 
Abdomen 9 (2.5) Exacerbation of COPD 8 (1.8) 
Pericardium 6 (1.7) Other
c
 158 (36.0) 
Brain 6 (1.7)   
Musculoskeletal 5 (1.4)   
Chest wall 2 (0.6)   
Other 31 (8.5)   
COPD, Chronic obstructive pulmonary disease 667 
a
Some patients had TB at multiple anatomical sites. 668 
b
Some patients had multiple diagnoses. 669 
c
Less than five cases per diagnosis. 670 
 671 
 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
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Table 4: Diagnostic accuracy of current and second-generation IGRAs for diagnosis of active TB. Sensitivity, specificity and predictive values are presented as 
percentages. 
 
Test performance 
T-SPOT.TB
a,e,f
 QFT-GIT
a,e,f
 ESAT+ CFP10 + Rv3615c
a,e,f
 CFP10 + Rv3615c + Rv3879c
a,e,f
 
n/N Estimate (95%CI) n/N Estimate (95%CI) n/N Estimate (95%CI) n/N Estimate (95%CI) 
Sensitivity for active TB         
All TB 253/311 81.4 (76.6–85.3) 220/327 67.3 (62.0–72.1) 273/306 89.2 (85.2–92.2) 263/299 88.0 (83.8–91.2) 
Culture-confirmed TB 185/218 84.9 (79.5–89.0) 163/231 70.6 (64.4–76.1) 203/216 94.0 (90.0–96.4) 197/211 93.4 (89.2–96.0) 
Highly-probable TB
b
 68/93 73.1 (63.3–81.1) 57/96 59.4 (49.4–68.7) 70/90 77.8 (68.2–85.1) 66/88 75.0 (65.0–82.9) 
Smear-positive TB
c
 45/55 81.8 (69.7–89.8) 42/56 75.0 (62.3–84.5) 48/51 94.1 (84.1–98.0) 47/50 94.0 (83.8–97.9) 
   Smear-negative TB
c,d
 169/206 82.0 (76.2–86.7) 148/222 66.7 (60.2–72.5) 183/207 88.4 (83.3–92.1) 176/202 87.1 (81.8–91.1) 
Pulmonary TB 79/105 75.2 (66.2–82.5) 79/115 68.7 (59.7–76.5) 88/100 88.0 (80.2–93.0) 85/97 87.6 (79.6–92.8) 
Extra-pulmonary TB 141/169 83.4 (77.1–88.3) 113/171 66.1 (58.7–72.8) 148/167 88.6 (82.9–92.6) 142/164 86.6 (80.5–91.0) 
Specificity for active TB         
Active TB excluded  319/370 86.2 (82.3–89.4) 304/378 80.4 (76.1–84.1) 296/370 80.0 (75.6–83.8) 296/372 79.6 (75.2–83.4) 
Active TB excluded, TST-
negative, no risk factors for LTBI 
87/93 93.5 (86.6–97.0) 85/91 93.4 (86.4–96.9) 84/92 91.3 (83.8–95.5) 84/93 90.3 (82.6–94.8) 
Predictive values for all TB         
Positive predictive value 253/304 83.2 (78.6–87.0) 220/294 74.8 (69.6–79.5) 273/347 78.7(74.1–82.7) 263/339 77.6 (72.8–81.7) 
Negative predictive value 319/377 84.6 (80.6–87.9) 304/411 74.0 (69.5–78.0) 296/329 90.0 (86.2–92.8) 296/332 89.2 (85.4–92.1) 
Likelihood ratios for all TB         
Positive likelihood ratio  5.90 (4.55–7.66)  3.44 (2.76–4.27)  4.46 (3.62–5.49)  4.31 (3.51–5.28) 
Negative likelihood ratio  0.22 (0.17–0.27)  0.41 (0.35–0.48)  0.13 (0.10–0.19)  0.15 (0.11–0.21) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
a
25/845 QFT-GIT and 36/845 T-SPOT.TB and second-generation IGRA results were missing due to blood draw difficulties, samples being unsuitable for testing, or samples 
being destroyed for laboratory reasons. Missing results were spread across all diagnostic categories. 
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b’Highly-probable’ TB includes culture-negative TB cases plus 10 patients with a final diagnosis of TB who did not have Mtb culture performed. Sensitivity (95%CI) results 
for culture-negative TB alone were as follows: T-SPOT.TB – 69.9% (59.3–78.7); QFT-GIT – 57.1% (46.5–67.2); second-generation IGRA (ESAT-6, CFP-10, Rv3615c) – 
75.0% (64.5–83.2); ESAT-6-free IGRA (CFP-10, Rv3615c, Rv3879c) – 73.1% (62.3–81.7).   
c
56/845 participants did not undergo smear microscopy. 
d
Among 165 patients who were smear-negative but culture-positive, 122/142 were T-SPOT.TB-positive; 105/153 were QFT-GIT-positive; 135/144 were positive in second-
generation IGRA and 131/141 were positive in ESAT-6-free IGRA. 
 e
Indeterminate and borderline IGRA results were excluded from the analysis and thus also from data presented in this table. Numbers of indeterminate and borderline results 
for T-SPOT.TB/QFT-GIT and second-generation IGRA are presented in the Appendix (Supplementary Tables 3 (page5) and 4 (page 6), respectively).  
f
When indeterminate and borderline results were included as test positives in sensitivity analyses (positive on the basis that such a result could not exclude a TB diagnosis), 
sensitivity (95%CI) results for all TB were as follows: T-SPOT.TB – 83.2% (78.9-86.8); QFT-GIT – 69.7% (64.7–74.2); second-generation IGRA (ESAT-6, CFP-10, 
Rv3615c) – 90.4% (86.9–93.1); ESAT-6-free IGRA (CFP-10, Rv3615c, Rv3879c) – 89.6% (85.9–92.4).   
 
 
 
 
 
 
